Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Based Therapy

Trial Profile

Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Based Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Doxorubicin liposomal; Lenalidomide; Pamidronic acid; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2018.
    • 10 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
    • 10 Aug 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top